8-K: Seres Therapeutics Faces Default Notice Over Manufacturing Milestone Payment

Seres Therapeutics received a notice of default from its lender, Oaktree, due to a dispute over a milestone payment to Bacthera and related notification requirements.

Summary

• Seres Therapeutics received a Notice of Default from Oaktree Fund Administration, the administrative agent for its lenders, on May 1, 2024.
• The notice claims that Seres defaulted on its credit agreement due to a non-payment of a $28 million milestone payment to Bacthera and failure to notify the agent of the non-payment.
• Seres disputes the default, stating the payment is not yet due as the manufacturing suite is not fully completed.
• The company also argues that even if the payment were due, it would not constitute 'Indebtedness' under the credit agreement.
• Seres has a $250 million term loan facility with Oaktree, of which $110 million is currently outstanding.
• The loan bears interest at SOFR plus a margin, with a potential reduction if certain sales targets are met.
• Oaktree could accelerate the loan and seize collateral if a default is confirmed.
• Seres intends to defend itself vigorously and pursue counterclaims if Oaktree takes action.
• The company is attempting to resolve the matter with Oaktree consensually.

Sentiment

Score: 3

Explanation: The document indicates a serious dispute with a lender, a potential default, and possible legal action, all of which are negative for the company's financial health and investor confidence.

Positives

• Seres believes the milestone payment is not yet due, as the manufacturing suite is not fully completed.
• The company is actively engaging in discussions with Bacthera to complete the project.
• Seres is attempting to resolve the issue with Oaktree consensually.
• Seres intends to vigorously defend itself and pursue counterclaims if Oaktree takes action.

Negatives

• Oaktree has issued a Notice of Default, indicating a serious disagreement over the terms of the credit agreement.
• The dispute centers around a $28 million milestone payment, which is a significant amount.
• There is a risk that Oaktree could accelerate the $110 million loan and seize collateral.
• The situation could lead to legal action and significant costs for Seres.

Risks

• The dispute with Oaktree could lead to acceleration of the $110 million loan and potential seizure of collateral.
• Legal action could be costly and time-consuming for Seres.
• The uncertainty surrounding the milestone payment and the manufacturing suite completion could impact investor confidence.
• Failure to resolve the dispute could negatively affect the company's financial stability.

Future Outlook

The company is working to complete the manufacturing suite and resolve the dispute with Oaktree, but there is no guarantee of a positive outcome. The company has stated that it may elect to update forward-looking statements in the future, but disclaims any obligation to do so.

Management Comments

• The Company believes that it is not in default under the Oaktree Credit Agreement.
• The Company intends to vigorously defend itself against any actions by Oaktree and pursue any counterclaims available to it.
• The Company is attempting to resolve this matter with the Agent consensually.

Industry Context

This situation highlights the risks associated with complex manufacturing agreements and the importance of clear communication with lenders. It is not uncommon for biotech companies to face challenges in scaling up manufacturing and meeting contractual obligations.

Comparison to Industry Standards

• Many biotech companies rely on contract manufacturing organizations (CMOs) like Bacthera, and disputes over milestone payments are not unheard of.
• The size of the loan facility and the interest rate are within the typical range for biotech companies at this stage of development.
• The potential for a default and legal action is a significant risk, and companies in similar situations often face challenges in maintaining investor confidence.
• Companies like Rebiotix (acquired by Ferring) and Finch Therapeutics have also faced manufacturing and financial challenges, highlighting the complexities of the microbiome therapeutics space.

Stakeholder Impact

• Shareholders face increased risk due to the potential default and legal action.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers may be concerned about the company's ability to deliver products.
• Suppliers and creditors may face increased risk of non-payment.

Next Steps

• Seres will continue discussions with Bacthera to complete the manufacturing suite.
• Seres will attempt to resolve the dispute with Oaktree consensually.
• Seres will vigorously defend itself against any actions by Oaktree and pursue counterclaims if necessary.

Key Dates

Keywords

default, credit agreement, milestone payment, Oaktree, Bacthera, loan, manufacturing, indebtedness, SOFR, legal